Eli Lilly and WuXi AppTec scored exits from the immunotherapy developer, which has seen its shares rocket 66% since it floated.

Immunocore, a UK-based bispecific immunotherapy developer backed by pharmaceutical firms Eli Lilly and WuXi AppTec, has floated on the Nasdaq Global Select Market having raised over $258m in its initial public offering.

The offering consisted of approximately 9.94 million American Depositary Shares priced at $26.00 each, above the offering’s $23 to $25 range. Immunocore concurrently completed a $15m private placement from Bill & Melinda Gates Foundation.

The company’s shares rose more than 66% to close at $43.20 on Friday,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn